68.10.Z - Buying and selling of own real estate
20.13.Z - Manufacture of other inorganic basic chemicals
20.14.Z - Manufacture of other organic basic chemicals
21.10.Z - Manufacture of basic pharmaceutical substances
21.20.Z - Manufacture of medicines and other pharmaceutical products
64.20.Z - Activities of holding companies
70.10.Z - Activities of head office and holding companies, excluding financial holding companies
72.11.Z - Research and experimental development on biotechnology
72.19.Z - Other research and experimental development on natural sciences and engineering
72.20.Z - Research and experimental development on social sciences and humanities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -2,3 | -6,5 | -2,4 | 63,3 |
EBITDA | -0,7 | -1,5 | -0,3 | 78 |
Short time liabilities | 1,3 | 0,9 | 0,8 | -11,4 |
Equity capital | 17,3 | 10,9 | 8,8 | -19,4 |
Operating profit (EBIT) | -0,7 | -1,5 | -0,3 | 78 |
Assets | 19,6 | 12,1 | 9,8 | -19,6 |
Net profit (loss) | -2,1 | -5,5 | -2,1 | 61,6 |
Cash | 2,3 | 0 | 0 | -74 |
Net income from sale | 0 | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 2,3 | 1,2 | 0,9 | -20,9 |
Working assets | 17,4 | 10,7 | 8,3 | -22,5 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | -12,4 | -50,6 | -24,1 | 26,5 |
Equity capital to total assets | 88,1 | 90,1 | 90,3 | 0,2 |
Gross profit margin | -23 288,1 | 1 806 408 | ||
EBITDA Margin | -6762,9 | 11 231 | ||
Days | Days | Days | Days | |
Short term commitment turnover cycle | 46 609 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 13.1488037109375 | 11.496440887451172 | 9.973487854003906 | -1,5 |
Net dept to EBITDA | 2.8718466758728027 | -0.2233930081129074 | -0.8797836303710938 | -0,7 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane